APA

Bakker A. B. H., Python C., Kissling C. J., Pandya P., Marissen W. E., Brink M. F., Lagerwerf F., Worst S., van Corven E., Kostense S., Hartmann K., Weverling G. J., Uytdehaag F., Herzog C., Briggs D. J., Rupprecht C. E., Grimaldi R. & Goudsmit J. (20090209). First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. : Vaccine.

Chicago

Bakker A B H, Python C, Kissling C J, Pandya P, Marissen W E, Brink M F, Lagerwerf F, Worst S, van Corven E, Kostense S, Hartmann K, Weverling G J, Uytdehaag F, Herzog C, Briggs D J, Rupprecht C E, Grimaldi R and Goudsmit J. 20090209. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. : Vaccine.

Harvard

Bakker A. B. H., Python C., Kissling C. J., Pandya P., Marissen W. E., Brink M. F., Lagerwerf F., Worst S., van Corven E., Kostense S., Hartmann K., Weverling G. J., Uytdehaag F., Herzog C., Briggs D. J., Rupprecht C. E., Grimaldi R. and Goudsmit J. (20090209). First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. : Vaccine.

MLA

Bakker A B H, Python C, Kissling C J, Pandya P, Marissen W E, Brink M F, Lagerwerf F, Worst S, van Corven E, Kostense S, Hartmann K, Weverling G J, Uytdehaag F, Herzog C, Briggs D J, Rupprecht C E, Grimaldi R and Goudsmit J. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. : Vaccine. 20090209.